 |
| Contact us |
|
| For media professionals: |
This contact information is for media professionals only. If you are not a member of the news media, please contact us via the phone number or email link at the bottom of the page.
|
|
| U.S. Communications: |
Lisa Buffington
(908) 981-6569
US.media-relations@sanofi-aventis.com
sanofi-aventis U.S.
55 Corporate Drive
Bridgewater, NJ 08807
Tel: 800-981-2491
|
| Via email |
|
|
|
|
 | 2006 Press Releases |
|
 | Press releases are intended for journalists, investors and shareholders. |
|
|
|
| December 15, 2006 |
| Sanofi-aventis statement regarding U.S. FDA joint advisory committee recommendation for KETEK® (telithromycin) |
|
|
|
|
| December 12, 2006 |
| New study shows LOVENOX® (enoxaparin sodium injection) is more effective than unfractionated heparin (UFH) for lowering the risk of venous thromboembolism (VTE) in patients with acute ischemic stroke |
|
|
|
|
| December 08, 2006 |
| Rimonabant update in the United States |
|
|
|
|
| December 05, 2006 |
| New data shows Rimonabant benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors |
|
|
|
|
| October 31, 2006 |
| First 9th months of 2006: Sales growth of 2.6% on a comparable basis - Adjusted EPS growth of 15.0%, or 7.5% excluding selected items |
|
|
|
|
| October 30, 2006 |
| New study shows SCULPTRA® (injectable poly-l-lactic acid), a unique class of injectable for cosmetic use, provides 13 month results |
|
|
|
|
| October 18, 2006 |
| FDA approves ALLEGRA® (fexofenadine hydrochloride) oral suspension for treatment of seasonal allergy symptoms and chronic idiopathic urticaria |
|
|
|
|
| October 18, 2006 |
| TAXOTERE® receives U.S. FDA approval for the treatment of patients with head and neck cancer |
|
|
|
|
| September 25, 2006 |
| Sanofi-aventis and UCB sign a co-promotion agreement for Xyzal® in the United States |
|
|
|
|
| September 19, 2006 |
| Dermik Laboratories announces FDA acceptance of supplemental filing application for SCULPTRA® |
|
|
|
|
| September 05, 2006 |
| New clinical data show enoxaparin significantly reduced the risk of repeat heart attack and stroke in patients undergoing percutaneous coronary intervention (PCI) |
|
|
|
|
| September 01, 2006 |
| Preliminary injunction ordered in PLAVIX® patent infringement case - Apotex to halt sales of unauthorized generic |
|
|
|
|
| August 17, 2006 |
| FDA approves new indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack |
|
|
|
|
| August 14, 2006 |
| The U.S. Food and Drug Administration approves ACTONEL® for broader use in men with osteoporosis |
|
|
|
|
| August 02, 2006 |
| Sanofi-aventis Announces First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis - Adjusted EPS growth of 32.9%,or 16.1% excluding selected items |
|
|
|
|
| July 12, 2006 |
| New data support long-term use of AMBIEN CR™ (zolpidem tartrate extended-release) Tablets CIV for up to 24 weeks |
|
|
|
|
| July 03, 2006 |
| Baseball Greats Team Up to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, “DVT Blood Clots: Know The Stats. Know Your Risk.” |
|
|
|
|
| June 29, 2006 |
| Sanofi-aventis announces update to KETEK® (telithromycin) U.S. prescribing information |
|
|
|
|
| June 20, 2006 |
| New data reveals that enoxaparin results in significant cost savings compared to Unfractionated Heparin (UFH) in treatment of in-hospital patients at risk for Venous Thromboembolism (VTE) |
|
|
|
|
| June 10, 2006 |
| New study shows an innovative mealtime insulin dosing algorithm may provide a safe and effective alternative to carbohydrate counting for patients with type 2 diabetes |
|
|
|
|
| June 06, 2006 |
| Studies Evaluating Eloxatin®-Based Regimens in Gastrointestinal Cancers Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
|
|
|
|
| June 03, 2006 |
| New Phase III data reports on the safety and efficacy of Risedronate for the treatment of male osteoporosis |
|
|
|
|
| June 03, 2006 |
| Results of a meta-analysis show benefits of TAXOTERE® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC) |
|
|
|
|
| June 01, 2006 |
| Sanofi-aventis General Meeting of Shareholders |
|
|
|
|
| May 30, 2006 |
| New ELOXATIN® and TAXOTERE® data in several tumor types to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) |
|
|
|
|
| May 22, 2006 |
| Sanofi-aventis announces steps to protect access to prescription drugs for low income medicare patients |
|
|
|
|
| May 16, 2006 |
| Star of the BatmanTM television series leads crusade for baby boomers to recognize importance of Benign Prostatic Hyperplasia (BPH) |
|
|
|
|
| May 15, 2006 |
| Yolanda King and African-American leaders across the country unite to fight stroke |
|
|
|
|
| May 05, 2006 |
| First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis. 52.8% growth in adjusted EPS and 19.8% excluding selected items. |
|
|
|
|
| April 10, 2006 |
| Appeals court rules in Sanofi-aventis’ favor in the U.S. LOVENOX® (enoxaparin sodium injection) patent infringement case |
|
|
|
|
| March 23, 2006 |
| TAXOTERE® receives U.S. FDA approval for use in advanced stomach cancer |
|
|
|
|
| March 20, 2006 |
| Statement responding to recent media reports regarding appropriate use of AMBIEN® (zolpidem tartrate) CIV in the U.S. |
|
|
|
|
| March 12, 2006 |
| New study furthers understanding of the role of dual antiplatelet therapy in the prevention of atherothrombotic events, including heart attack, stroke or cardiovascular death in broad population |
|
|
|
|
| February 28, 2006 |
| APIDRA® - a new rapid-acting insulin analog - is now available in the United States for hyperglycemia in adults with type 2 and type 1 diabetes |
|
|
|
|
| February 24, 2006 |
| Sanofi-aventis reports strong growth of 25.7% in 2005 adjusted EPS - Nearly 90% of synergies delivered by end 2005 - Dividend increased by 26.7% |
|
|
|
|
| February 17, 2006 |
| Sanofi-aventis received from the FDA an approvable letter for rimonabant for weight management and a non approvable letter for smoking cessation |
|
|
|
|
| February 14, 2006 |
| The Journal of the American Medical Association publishes the RIO-North America study |
|
|
|
|
| January 30, 2006 |
| Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis |
|
|
|
|
| January 18, 2006 |
| FDA grants priority review to PLAVIX® (clopidogrel bisulfate) Supplemental New Drug Application (sNDA) for additional type of heart attack |
|
|
|
|
| January 13, 2006 |
| Pfizer to purchase Sanofi-aventis rights to EXUBERA® in application of change of control clauses |
|
|
|
|
| January 04, 2006 |
| Procter & Gamble Pharmaceuticals and Sanofi-aventis US LLC file lawsuit against Roche Pharmaceuticals and Glaxosmithkline |
|
|
|
|
|
|
